US · Healthcare · Biotechnology
EPS came in at 0.08 against a street estimate of 0.09 — a miss of 11.1%.
Analysts rate Precigen Inc a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $13.65.
CONFIDENT Papsimius (RRP therapy) hit $53.1M Q2 revenue, +145% QoQ, driving company to profitability pre-FDA anniversary. 315M covered lives, 500+ hub patients, expanding ex-hub adoption. Platform potential in HPV oncology via PRGN 2009. Q2 2026 No geographic breakdown provided; U.S.-focused discussion. Analysts probed Q3 growth sustainability, accounting purity, and patient pool penetration. Management declined Q3 guidance but emphasized leading indicators (payer activation, J-code boost, non-hub adoption) support continued growth; acknowledged math dictates deceleration but reaffirmed early-launch position with substantial runway. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| Patients Capital Management LLC | 5.32% |
| BlackRock Inc | 4.79% |
| State Street Corp | 3.35% |
| Diametric Capital, LP | 2.59% |
| Vanguard Capital Management, LLC | 2.21% |
| TANG CAPITAL MANAGEMENT LLC | 1.79% |
| Boxer Capital Management, LLC | 1.44% |
| Geode Capital Management, LLC | 1.40% |
| Document | Date |
|---|---|
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 PAPZIMEOS net revenue rose 37% quarter-over-quarter to $72.9 million. Launch-to-date net product revenue reache | 2026-11-05 |
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $74,148, compared with $2,922 in the third quarter of 2025. • Nine-month 2026 revenue was $152,378 | 2026-11-04 |
| Quarterly report · Q2 2026 PRECIGEN, INC. – FORM 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $16.3 million in cash, $21.9 million in short-term investments, $0.5 | 2026-08-04 |
| Results announced · Q3 2026 PRECIGEN Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 net income: $20.1 million ($0.06 per basic share, $0.05 per diluted share) vs. | 2026-08-04 |
| Board / officer change · Q2 2026 PRECIGEN, INC. (PGEN) - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 18, 2026 • 7 million additional shares approved for | 2026-06-24 |
| Quarterly report · Q1 2026 PRECIGEN, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Product revenues (Q1 2026): $21,828K vs. $203K in Q1 2025 – representing first meaningful c | 2026-05-13 |
| Results announced · Q2 2026 PRECIGEN Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q1 2026 Product Revenue: $21.6 million from PAPZIMEOS, the company's first commercial | 2026-05-13 |
| Proxy statement · Q2 2026 PRECIGEN, INC. — 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect nine director nominees to serve one-year term | 2026-04-30 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Precigen Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.